LFCR Q4 2022 Earnings — Lifecore Biomedical, Inc. Revenue & Financial Results | Market Cap Arena

LFCRLifecore Biomedical, Inc.

$267M

Q4 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$48M-65.9% YoY

Gross Profit

$11M23.8% margin

Operating Income

-$39M-81.8% margin

Net Income

-$37M-77.0% margin

EPS (Diluted)

$-1.24

QoQ Revenue Growth

+27.4%

Cash Flow

Operating Cash Flow

$36,000

Free Cash Flow

-$10M

Stock-Based Comp.

$680,000

Balance Sheet

Total Assets

$275M

Total Liabilities

$187M

Stockholders' Equity

$88M

Cash & Equivalents

$991,000

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$140M	-65.9%
Gross Profit	$11M	$25M	-54.3%
Operating Income	-$39M	$1M	-3260.8%
Net Income	-$37M	-$3M	-1179.2%